OR WAIT null SECS
November 01, 2008
There are many challenges upstream and downstream in manufacturing a biotech drug.
Richard Kilner, Managing Director of the Commonwealth of Pennsylvania European Investment Office, is incredibly enthusiastic about both his State and the potential it offers investors: "We are the number one State in pharmaceuticals (by number of establishments, employment and GDP output) and rapidly closing in on Massachusetts, the number two in biotech."
Access to the capital markets of the US has always been a key attraction for Europe's biotech businesses.
Many compounds fail in preclinical development because of safety-related problems, but identifying 'predictable' safety or toxicity liabilities earlier in the process could lead to improved design and selection of compounds that are more likely to be approved.
California's forward-thinking reputation, well-funded research universities and world leadership in the potentially life-saving field of stem cell research and green energy provide a progressive and positive business environment for biotech companies.
Speaking to Pharmaceutical Technology Europe, Georgia Bio's Director of Innovation and Technology, Carol Henderson, outlined the unique assets that make Georgia an attractive location for international bioscience companies.
According to Deputy Director, Alexander Bothmann, of Enterprise Florida Inc., in Germany, the 'Sunshine State' is: "Committed to building a world-class biotechnology sector by investing in research facilities, fostering the growth of local biotech companies and welcoming progressive newcomers, such as the Scripps Research Institute, the Burnham Institute for Medical Research and Torrey Pines Institute for Molecular Studies."
October 01, 2008
...an uninformed decision based on commercial requirements alone may, ultimately, have disastrous consequences on the efficacy of the target recombinants.
September 11, 2008
FDA has issued a Final Rule titled "Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals."
September 01, 2008
We have to make the politicians understand that if we don't take biotech seriously then tourism will be our premier industry in the future.